谷氨酰胺酶抑制剂CB-839靶向JAK2突变骨髓增殖性肿瘤造血的代谢依赖性
在JAK2-V617F突变驱动的骨髓增殖性肿瘤(MPN)小鼠模型中,谷氨酰胺酶抑制剂CB-839降低骨髓细胞线粒体呼吸率,体内治疗使血糖正常化、缩小脾脏并减少红细胞增多,且优先降低JAK2突变造血干细胞比例;与芦可替尼或3PO联用效果更明显,并抑制真性红细胞增多症患者CD34+细胞增殖。
要点
- CB-839显著降低JAK2-V617F突变小鼠骨髓细胞线粒体呼吸率,示其对谷氨酰胺来源ATP的依赖。
- CB-839体内治疗使V617F小鼠血糖正常化、缩小脾脏并减少红细胞增多。
- CB-839优先降低JAK2突变造血干细胞比例,与芦可替尼联用强烈减轻晚期骨髓纤维化。
核心结论
- 抑制谷氨酰胺酶单用或联合糖酵解抑制剂或JAK2抑制剂,可能代表一种有吸引力的MPN新治疗策略。
研究设计与样本
- 研究使用JAK2-V617F突变小鼠骨髓细胞及真性红细胞增多症患者CD34+造血干/祖细胞,检测CB-839对谷氨酰胺分解的药理学抑制效果。
主要发现
- CB-839强烈降低JAK2-V617F突变(VF)小鼠骨髓细胞的线粒体呼吸率。
- CB-839体内治疗使VF小鼠血糖水平正常化、缩小脾脏并减少红细胞增多。
- CB-839与芦可替尼或糖酵解抑制剂3PO联用时上述效果更明显。
- CB-839优先降低JAK2突变造血干细胞比例,总造血干细胞数减少主要因G1期造血干细胞减少。
- CB-839联合芦可替尼强烈减轻MPN晚期骨髓纤维化;纳摩尔浓度CB-839抑制真性红细胞增多症患者CD34+细胞增殖。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hyperproliferation of myeloid and erythroid cells in myeloproliferative neoplasms (MPN) driven by the JAK2-V617F mutation is associated with altered metabolism. Given the central role of glutamine in anabolic and catabolic pathways, we examined the effects of pharmacologically inhibiting glutaminolysis, that is, the conversion of glutamine (Gln) to glutamate (Glu), using CB-839, a small molecular inhibitor of the enzyme glutaminase (GLS). We show that CB-839 strongly reduced the mitochondrial respiration rate of bone marrow cells from JAK2-V617F mutant (VF) mice, demonstrating a marked dependence of these cells on Gln-derived ATP production. Consistently, in vivo treatment with CB-839 normalized blood glucose levels, reduced splenomegaly and decreased erythrocytosis in VF mice. These effects were more pronounced when CB-839 was combined with the JAK1/2 inhibitor ruxolitinib or the glycolysis inhibitor 3PO, indicating possible synergies when cotargeting different metabolic and oncogenic pathways. Furthermore, we show that the inhibition of glutaminolysis with CB-839 preferentially lowered the proportion of JAK2-mutant hematopoietic stem cells (HSCs). The total number of HSCs was decreased by CB-839, primarily by reducing HSCs in the G1 phase of the cell cycle. CB-839 in combination with ruxolitinib also strongly reduced myelofibrosis at later stages of MPN. In line with the effects shown in mice, proliferation of CD34+ hematopoietic stem and progenitor cells from polycythemia vera patients was inhibited by CB-839 at nanomolar concentrations. These data suggest that inhibiting GLS alone or in combination with inhibitors of glycolysis or JAK2 inhibitors represents an attractive new therapeutic approach to MPN.
引用
- Usart M, Hansen N, Stetka J, et al. The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN. Blood Adv. 2024. PMID: 38295283. doi:10.1182/bloodadvances.2023010950
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。